Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness
Open Access
- 7 October 2015
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 7 (1) , 4-17
Abstract
Type 2 diabetes (T2D) is a highly prevalent disorder that affects millions of people worldwide. The hallmark of T2D is hyperglycemia and, while many treatment modalities exist, achieving and maintaining glycemic control can be challenging. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an appealing treatment option as they improve glycemic control, reduce weight, and limit the risk of hypoglycemia. Lixisenatide is a once-daily GLP-1 RA that has been evaluated in the GetGoal clinical trial program and has demonstrated efficacy and tolerability across a spectrum of patients. The feature that most distinguishes lixisenatide from other GLP-1 RAs is its ability to substantially reduce postprandial glucose (PPG) for the meal immediately following injection. Because of its positive effects on PPG, lixisenatide is being considered as a replacement for prandial insulin, and a fixed dose combination product containing lixisenatide and basal insulin is in development. Lixisenatide is a promising new addition to the antidiabetic armamentarium, but due to the lack of real-world experience with the drug, its exact place in therapy is unknown.Keywords
This publication has 25 references indexed in Scilit:
- Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitusDiabetes, Metabolic Syndrome and Obesity, 2013
- Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal ‐P)Diabetes, Obesity and Metabolism, 2013
- Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metforminDiabetes, Obesity and Metabolism, 2013
- Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)Diabetes, Obesity and Metabolism, 2012
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in MonotherapyDiabetes Care, 2012
- Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetesRegulatory Peptides, 2010
- Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled trialDiabetic Medicine, 2010
- Association of Pancreatitis with Glucagon-Like Peptide-1 Agonist UseAnnals of Pharmacotherapy, 2010
- Glucagon-like peptide-1, glucose homeostasis and diabetesTrends in Molecular Medicine, 2008